TY - JOUR
T1 - Ectopic overexpression of haem oxygenase-1 protects kidneys from carboplatin-mediated apoptosis
AU - Sue, Yuh Mou
AU - Cheng, Ching Feng
AU - Chou, Ying
AU - Chang, Chih Cheng
AU - Lee, Pei Shan
AU - Juan, Shu Hui
PY - 2011/4
Y1 - 2011/4
N2 - BACKGROUND AND PURPOSE: We previously reported that the activation of the nuclear factor of activated T-lymphocyte-3 (NFAT3) by carboplatin leads to renal apoptosis as a result of oxidative stress, which is reversed by N-acetylcysteine. Herein, we extend our previous work to provide evidence of the molecular mechanisms of haem oxygenase (HO)-1 in protecting against injury. EXPERIMENTAL APPROACH Protective mechanisms of HO-1 in carboplatin-mediated renal apoptosis were examined in C57BL/6 mice and rat renal tubular cells (RTC) with HO-1 induction or inactivation/knockdown. KEY RESULTS The HO-1, induced by cobalt protoporphyrin, protected against carboplatin-induced renal injury in vivo. This protection was decreased by an inhibitor of HO-1 action, tin protoporphyrin. In cultures of RTC, carboplatin-induced apoptosis was similarly affected by HO-1 overexpression or knockdown. Carboplatin-mediated NFAT3 activation and apoptosis involve activation of the signalling kinases, extracellular signal regulated kinase, Jun N-terminal kinase and protein kinase C, and such activation was reversed in cells overexpressing HO-1. Both products of the HO-1 reaction, CO and bilirubin, inhibited (by 30-40%) NFAT3 activation and production of the pro-apoptotic proteins Bcl-XS/Bax. Additionally, the activation of NFκB was markedly decreased by HO-1 induction. CONCLUSION AND IMPLICATIONS HO-1 and its reaction products show anti-apoptotic effects in carboplatin-mediated renal injury. A novel functional NFAT3 binding site identified in the rat HO-1 promoter region was involved in producing a 1.5-fold to 2.5-fold increase in HO-1 induction by carboplatin. Nevertheless, only HO-1 overexpression and activation prior to the carboplatin challenge provided protection against carboplatin-induced injury.
AB - BACKGROUND AND PURPOSE: We previously reported that the activation of the nuclear factor of activated T-lymphocyte-3 (NFAT3) by carboplatin leads to renal apoptosis as a result of oxidative stress, which is reversed by N-acetylcysteine. Herein, we extend our previous work to provide evidence of the molecular mechanisms of haem oxygenase (HO)-1 in protecting against injury. EXPERIMENTAL APPROACH Protective mechanisms of HO-1 in carboplatin-mediated renal apoptosis were examined in C57BL/6 mice and rat renal tubular cells (RTC) with HO-1 induction or inactivation/knockdown. KEY RESULTS The HO-1, induced by cobalt protoporphyrin, protected against carboplatin-induced renal injury in vivo. This protection was decreased by an inhibitor of HO-1 action, tin protoporphyrin. In cultures of RTC, carboplatin-induced apoptosis was similarly affected by HO-1 overexpression or knockdown. Carboplatin-mediated NFAT3 activation and apoptosis involve activation of the signalling kinases, extracellular signal regulated kinase, Jun N-terminal kinase and protein kinase C, and such activation was reversed in cells overexpressing HO-1. Both products of the HO-1 reaction, CO and bilirubin, inhibited (by 30-40%) NFAT3 activation and production of the pro-apoptotic proteins Bcl-XS/Bax. Additionally, the activation of NFκB was markedly decreased by HO-1 induction. CONCLUSION AND IMPLICATIONS HO-1 and its reaction products show anti-apoptotic effects in carboplatin-mediated renal injury. A novel functional NFAT3 binding site identified in the rat HO-1 promoter region was involved in producing a 1.5-fold to 2.5-fold increase in HO-1 induction by carboplatin. Nevertheless, only HO-1 overexpression and activation prior to the carboplatin challenge provided protection against carboplatin-induced injury.
KW - ERK/JNK
KW - PKC
KW - apoptosis
KW - carboplatin
KW - haem oxygenase-1
KW - nuclear factor of activated T-lymphocytes
KW - reactive oxygen species
KW - renal tubular cells
UR - http://www.scopus.com/inward/record.url?scp=79953038261&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79953038261&partnerID=8YFLogxK
U2 - 10.1111/j.1476-5381.2010.01189.x
DO - 10.1111/j.1476-5381.2010.01189.x
M3 - Article
C2 - 21198546
AN - SCOPUS:79953038261
SN - 0007-1188
VL - 162
SP - 1716
EP - 1730
JO - British Journal of Pharmacology
JF - British Journal of Pharmacology
IS - 8
ER -